Beta Bionics
Beta Bionics' revenue rose 53.9% to $100 million in fiscal 2025. Its operating margin was −71.5%, down from −69.5% a year earlier. Free cash flow was −$56 million. The diluted share count rose 536.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Beta Bionics does
Beta Bionics makes the iLet Bionic Pancreas, an automated insulin delivery system for people with diabetes who need insulin. It uses an adaptive closed-loop algorithm, meaning software that adjusts insulin doses on its own to simplify daily management. The U.S. Food and Drug Administration cleared the iLet for Type 1 diabetes in adults and children six and older, and it launched in the United States in May 2023.
The company has no other commercial products. It relies on sales of the iLet and related single-use products for all of its revenue. It says its installed base had grown to 35,011 iLets by the end of 2025. It competes with makers of other insulin pumps and diabetes devices, most of which have far greater resources.
Beta Bionics describes itself as a commercial-stage company with limited experience in marketing and selling its products. Its device is under a post-market surveillance order from the FDA.
Its biggest risks, as it describes them
- It has a limited sales history and has lost money since it started.
- All its revenue comes from the iLet and related single-use products.
- Competitors with far greater resources could win customers or make the iLet less desirable.
- The FDA's post-market surveillance order could force changes to, or a recall of, the iLet.
- It may need to raise more money, which may not be available on acceptable terms.
Income statement
Beta Bionics lost money in fiscal 2025: a net loss of $73 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 97 | 104 | 219 |
| Debt incl. finance leases | — | — | — |
| Net debt (negative means net cash) | — | — | — |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | — |
| Interest coverage | — | — | — |
| Current ratio | 9.8x | 6.3x | 8.7x |
| Quick ratio | 9.7x | 5.7x | 8.0x |
Cash flow
Projections
Project Beta Bionics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Beta Bionics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | 363.6% | −2.1% |
| Altman Z'' | −7.10 | 6.94 |
| Accruals ratio | −5.0% | −9.3% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Pass |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | Fail | Pass |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | Pass | Pass |
| Revenue rose relative to assets | — | Pass |
| F-score | — | — |
Compare
Put Beta Bionics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Beta Bionics | FY25 | 53.9% | −71.5% | −56.1% | — | — | — | |
| Butterfly Network | FY25 | 19.0% | −88.5% | −16.4% | — | — | — | Compare |
| Kestra Medical Technologies | FY26 | 59.0% | −141.6% | −122.6% | — | — | 4 | Compare |
| Ceribell | FY25 | 36.1% | −65.6% | −46.7% | — | — | — | Compare |
| Delcath Systems | FY25 | 129.1% | 0.8% | 24.6% | 2.8% | −101.4x | 6 | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 12 | 65 | 100 |
| Revenue growth | — | 442.9% | 53.9% |
| Gross profit | 6 | 36 | 56 |
| Research and development | 18 | 26 | 35 |
| Operating income | −36 | −45 | −72 |
| Net income | −44 | −55 | −73 |
| Diluted EPS (US$) | −8.31 | −8.60 | −1.81 |
| Diluted shares (millions) | 5 | 6 | 40 |
| Cash flow | |||
| Cash from operations | −32 | −48 | −51 |
| Capital expenditure | 0 | 3 | 5 |
| Free cash flow | −33 | −52 | −56 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 6 | 6 | 16 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 97 | 104 | 219 |
| Debt incl. finance leases | — | — | — |
| Total assets | 110 | 150 | 329 |
| Total liabilities | 51 | 74 | 41 |
| Shareholders' equity | −203 | −245 | 288 |
| Margins and ratios | |||
| Gross margin | 52.6% | 55.1% | 55.4% |
| Operating margin | −298.9% | −69.5% | −71.5% |
| Net margin | −367.6% | −84.1% | −73.0% |
| Free cash flow margin | −273.8% | −79.3% | −56.1% |
| Rule of 40 (growth + FCF margin) | — | 363.6% | −2.1% |
| Return on capital | — | — | — |
| Return on equity | — | — | −346.5% |
| Return on assets | — | −42.2% | −30.6% |
| Net debt to EBITDA | — | — | — |